Get the Stockscreener App
0.40
17.65%
0.06
After Hours:
.41
0.010
+2.50%
Fibrobiologics Inc stock is traded at $0.40, with a volume of 1.78M.
It is up +17.65% in the last 24 hours and up +62.27% over the past month.
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
See More
Previous Close:
$0.34
Open:
$0.3531
24h Volume:
1.78M
Relative Volume:
0.94
Market Cap:
$26.61M
Revenue:
-
Net Income/Loss:
$-17.78M
P/E Ratio:
-0.7283
EPS:
-0.5492
Net Cash Flow:
$-10.52M
1W Performance:
+19.44%
1M Performance:
+62.27%
6M Performance:
-39.58%
1Y Performance:
-75.00%
1-Day Range:
$0.3505
$0.4069
1-Week Range:
$0.31
$0.4069
52-Week Range:
$0.2201
$2.00
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.40 | 22.62M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
FibroBiologics to Present at the DealFlow Discovery Conference - manilatimes.net
Biotech with 270+ patents meets investors at DealFlow Discovery - Stock Titan
Risk Recap: Is FibroBiologics Inc stock a smart retirement pickJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Aug EndMonth: Why retail investors favor FibroBiologics Inc stockJuly 2025 Snapshot & Safe Swing Trade Setups - Bộ Nội Vụ
Levels Update: Why retail investors favor FibroBiologics Inc stock2025 AllTime Highs & Long-Term Safe Investment Ideas - Bộ Nội Vụ
How FibroBiologics Inc. stock benefits from strong dollarWeekly Trade Summary & Long-Term Growth Stock Strategies - Улправда
Why analysts remain bullish on FibroBiologics Inc. stockTrade Risk Summary & Consistent Profit Trading Strategies - Улправда
Will FibroBiologics Inc. stock remain a Wall Street favoriteWeekly Loss Report & Reliable Price Action Trade Plans - Улправда
Why FibroBiologics Inc. stock is a must watch in 2025July 2025 Breakouts & Verified Swing Trading Watchlists - Улправда
FibroBiologics faces Nasdaq delisting, plans reverse split - MSN
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 - Yahoo Finance
FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 - Investing.com Nigeria
Why FibroBiologics Inc. (SG0) stock attracts wealthy investorsStock Market Trends & Minimize Portfolio Damage with Warnings - ulpravda.ru
FibroBiologics CEO Issues Letter to Shareholders - markets.businessinsider.com
FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 By Investing.com - Investing.com South Africa
How a little-known biotech uses fibroblast cells against chronic disease - Stock Titan
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at D. Boral Capital - Defense World
How interest rate cuts could boost FibroBiologics Inc. stock2026 world cup usa national team round of 16 defensive leaders possession football expert forecast insights - Улправда
FibroBiologics (FBLG) Rating Maintained as "Buy" by D. Boral Cap - GuruFocus
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference - The Manila Times
FibroBiologics reports positive results for disc degeneration therapy By Investing.com - Investing.com Nigeria
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte Spheroid Therapy for Degenerative Disc Disease - marketscreener.com
FibroBiologics reports positive results for disc degeneration therapy - Investing.com
FibroBiologics Announces Positive Preclinical Results for a - GlobeNewswire
Fibrobiologics files IND for CYPS-317 to treat psoriasis - BioWorld MedTech
About Us - FinancialContent
FibroBiologics Advances Psoriasis Therapy Pipeline Through FDA IND Filing For CYPS317 - Voice Of HealthCare
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at HC Wainwright - Defense World
FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split - TipRanks
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal By Investing.com - Investing.com South Africa
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal - Investing.com
FibroBiologics Received Notice of Delisting - TradingView — Track All Markets
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing - Investing.com Canada
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing By Investing.com - Investing.com South Africa
FBLG: HC Wainwright & Co. Reiterates Buy Rating with Price Targe - GuruFocus
Fibrobiologics stock rises after FDA filing for psoriasis treatment - Investing.com India
Fibrobiologics stock rises after FDA filing for psoriasis treatment By Investing.com - Investing.com South Africa
FibroBiologics files IND application for psoriasis treatment By Investing.com - Investing.com Nigeria
FibroBiologics files IND application for psoriasis treatment - Investing.com India
FibroBiologics Announces IND Filing for CYPS317 Therapy for Moderate to Severe Psoriasis - Quiver Quantitative
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):